company background image
IVX

InvionASX:IVX Stock Report

Market Cap

AU$76.2m

7D

7.7%

1Y

27.3%

Updated

20 Oct, 2021

Data

Company Financials
IVX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

IVX Overview

Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia.

Price History & Performance

Summary of all time highs, changes and price drops for Invion
Historical stock prices
Current Share PriceAU$0.014
52 Week HighAU$0.008
52 Week LowAU$0.02
Beta1.85
1 Month Change-6.67%
3 Month Change0%
1 Year Change27.27%
3 Year Change-44.00%
5 Year Change366.67%
Change since IPO-96.46%

Recent News & Updates

Mar 23
Estimating The Intrinsic Value Of Invion Limited (ASX:IVX)

Estimating The Intrinsic Value Of Invion Limited (ASX:IVX)

Does the March share price for Invion Limited ( ASX:IVX ) reflect what it's really worth? Today, we will estimate the...

Nov 26
We Think Invion (ASX:IVX) Can Easily Afford To Drive Business Growth

We Think Invion (ASX:IVX) Can Easily Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

IVXAU PharmaceuticalsAU Market
7D7.7%1.8%1.7%
1Y27.3%5.8%20.2%

Return vs Industry: IVX exceeded the Australian Pharmaceuticals industry which returned 5.8% over the past year.

Return vs Market: IVX exceeded the Australian Market which returned 20.2% over the past year.

Price Volatility

Is IVX's price volatile compared to industry and market?
IVX volatility
IVX Beta1.85
Industry Beta1.3
Market Beta1

Stable Share Price: IVX is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: IVX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
2000n/aThian Chewhttps://www.inviongroup.com

Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a chlorophyll-based photosensitizer to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion’s IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer.

Invion Fundamentals Summary

How do Invion's earnings and revenue compare to its market cap?
IVX fundamental statistics
Market CapAU$76.24m
Earnings (TTM)-AU$1.48m
Revenue (TTM)AU$2.33m

35.9x

P/S Ratio

-56.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IVX income statement (TTM)
RevenueAU$2.33m
Cost of RevenueAU$1.52m
Gross ProfitAU$810.51k
ExpensesAU$2.29m
Earnings-AU$1.48m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.00025
Gross Margin34.79%
Net Profit Margin-63.65%
Debt/Equity Ratio0.0%

How did IVX perform over the long term?

See historical performance and comparison

Valuation

Is Invion undervalued compared to its fair value and its price relative to the market?

37.0%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: IVX (A$0.01) is trading below our estimate of fair value (A$0.02)

Significantly Below Fair Value: IVX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: IVX is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.

PE vs Market: IVX is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IVX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IVX is overvalued based on its PB Ratio (17.3x) compared to the AU Pharmaceuticals industry average (3.5x).


Future Growth

How is Invion forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

67.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Invion has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Invion performed over the past 5 years?

12.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IVX is currently unprofitable.

Growing Profit Margin: IVX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IVX is unprofitable, but has reduced losses over the past 5 years at a rate of 12.9% per year.

Accelerating Growth: Unable to compare IVX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IVX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).


Return on Equity

High ROE: IVX has a negative Return on Equity (-30.96%), as it is currently unprofitable.


Financial Health

How is Invion's financial position?


Financial Position Analysis

Short Term Liabilities: IVX's short term assets (A$1.1M) exceed its short term liabilities (A$851.5K).

Long Term Liabilities: IVX has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: IVX is debt free.

Reducing Debt: IVX has no debt compared to 5 years ago when its debt to equity ratio was 21.9%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable IVX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: IVX is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 58% per year.


Dividend

What is Invion current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IVX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IVX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IVX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IVX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IVX's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average board tenure


CEO

Thian Chew

1

Tenure

AU$367,825

Compensation

Mr. Thian Chew has been Executive Chairman and Chief Executive Officer at Invion Limited since November 1, 2020 and also served as Interim Chief Executive Officer since October 31, 2020 until November 1, 2...


CEO Compensation Analysis

Compensation vs Market: Thian's total compensation ($USD275.01K) is about average for companies of similar size in the Australian market ($USD302.06K).

Compensation vs Earnings: Thian's compensation has increased whilst the company is unprofitable.


Board Members

Experienced Board: IVX's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: IVX insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.6%.


Top Shareholders

Company Information

Invion Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Invion Limited
  • Ticker: IVX
  • Exchange: ASX
  • Founded: 2000
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$76.243m
  • Shares outstanding: 5.86b
  • Website: https://www.inviongroup.com

Number of Employees


Location

  • Invion Limited
  • 100 Albert Road
  • Level 4
  • Melbourne
  • Victoria
  • 3205
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/20 07:04
End of Day Share Price2021/10/20 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.